Lee H - Search Results

1

IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.

Lee JH, Lee H, Yun SM, Jung KH, Jeong Y, Yan HH, Hong S, Hong SS. Lee JH, et al. Among authors: lee h. Cancer Lett. 2013 Feb 1;329(1):99-108. doi: 10.1016/j.canlet.2012.10.028. Epub 2012 Nov 8. Cancer Lett. 2013. PMID: 23142281

2

Deguelin inhibits human hepatocellular carcinoma by antiangiogenesis and apoptosis.

Lee JH, Lee DH, Lee HS, Choi JS, Kim KW, Hong SS. Lee JH, et al. Oncol Rep. 2008 Jul;20(1):129-34. Oncol Rep. 2008. PMID: 18575727

3

Anti-cancer effects of a novel compound HS-113 on cell growth, apoptosis, and angiogenesis in human hepatocellular carcinoma cells.

Choi MJ, Jung KH, Kim D, Lee H, Zheng HM, Park BH, Hong SW, Kim MH, Hong S, Hong SS. Choi MJ, et al. Among authors: lee h. Cancer Lett. 2011 Jul 28;306(2):190-6. doi: 10.1016/j.canlet.2011.03.005. Epub 2011 Apr 3. Cancer Lett. 2011. PMID: 21463918

4

A novel imidazopyridine analogue as a phosphatidylinositol 3-kinase inhibitor against human breast cancer.

Lee H, Li GY, Jeong Y, Jung KH, Lee JH, Ham K, Hong S, Hong SS. Lee H, et al. Among authors: lee jh. Cancer Lett. 2012 May 1;318(1):68-75. doi: 10.1016/j.canlet.2011.12.001. Epub 2011 Dec 8. Cancer Lett. 2012. PMID: 22155744

5

HS-116, a novel phosphatidylinositol 3-kinase inhibitor induces apoptosis and suppresses angiogenesis of hepatocellular carcinoma through inhibition of the PI3K/AKT/mTOR pathway.

Jung KH, Choi MJ, Hong S, Lee H, Hong SW, Zheng HM, Lee HS, Hong S, Hong SS. Jung KH, et al. Among authors: lee h, lee hs. Cancer Lett. 2012 Mar 28;316(2):187-95. doi: 10.1016/j.canlet.2011.10.037. Epub 2011 Nov 4. Cancer Lett. 2012. PMID: 22182943

6

The effect of HS-111, a novel thiazolamine derivative, on apoptosis and angiogenesis of hepatocellular carcinoma cells.

Choi MJ, Lee H, Lee JH, Jung KH, Kim D, Hong S, Hong SS. Choi MJ, et al. Among authors: lee h, lee jh. Arch Pharm Res. 2012 Mar;35(4):747-54. doi: 10.1007/s12272-012-0420-4. Epub 2012 May 3. Arch Pharm Res. 2012. PMID: 22553069

7

Suppression of tumor proliferation and angiogenesis of hepatocellular carcinoma by HS-104, a novel phosphoinositide 3-kinase inhibitor.

Jung KH, Zheng HM, Jeong Y, Choi MJ, Lee H, Hong SW, Lee HS, Son MK, Lee S, Hong S, Hong SS. Jung KH, et al. Among authors: lee h, lee hs, lee s. Cancer Lett. 2013 Jan 1;328(1):176-87. doi: 10.1016/j.canlet.2012.08.005. Epub 2012 Aug 15. Cancer Lett. 2013. PMID: 22902995

8

HS-173, a novel phosphatidylinositol 3-kinase (PI3K) inhibitor, has anti-tumor activity through promoting apoptosis and inhibiting angiogenesis.

Lee H, Jung KH, Jeong Y, Hong S, Hong SS. Lee H, et al. Cancer Lett. 2013 Jan 1;328(1):152-9. doi: 10.1016/j.canlet.2012.08.020. Epub 2012 Aug 26. Cancer Lett. 2013. PMID: 22929971

9

A novel imidazopyridine derivative, HS-106, induces apoptosis of breast cancer cells and represses angiogenesis by targeting the PI3K/mTOR pathway.

Li GY, Jung KH, Lee H, Son MK, Seo J, Hong SW, Jeong Y, Hong S, Hong SS. Li GY, et al. Among authors: lee h. Cancer Lett. 2013 Feb 1;329(1):59-67. doi: 10.1016/j.canlet.2012.10.013. Epub 2012 Oct 17. Cancer Lett. 2013. PMID: 23085493

10

Synergistic anticancer activity of HS-173, a novel PI3K inhibitor in combination with Sorafenib against pancreatic cancer cells.

Yun SM, Jung KH, Lee H, Son MK, Seo JH, Yan HH, Park BH, Hong S, Hong SS. Yun SM, et al. Among authors: lee h. Cancer Lett. 2013 May 1;331(2):250-61. doi: 10.1016/j.canlet.2013.01.007. Epub 2013 Jan 20. Cancer Lett. 2013. PMID: 23340175

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

75,386 results

Search Page

Filters